<SEC-DOCUMENT>0001193125-12-500248.txt : 20121212
<SEC-HEADER>0001193125-12-500248.hdr.sgml : 20121212
<ACCEPTANCE-DATETIME>20121212170449
ACCESSION NUMBER:		0001193125-12-500248
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121206
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121212
DATE AS OF CHANGE:		20121212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-176897
		FILM NUMBER:		121259812

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d450150d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): December&nbsp;6, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Amarin Corporation plc </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>England and Wales</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21392</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ireland</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Former name or former address, if changed since last report </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;6, 2012, Amarin Corporation plc (the &#147;<U>Company</U>&#148;) and a subsidiary (collectively with the Company,
&#147;<U>Amarin</U>&#148;) entered into a financing agreement with Biopharma Secured Debt Fund II Holdings Cayman LP, a Cayman Islands exempted limited partnership (&#147;<U>Biopharma</U>&#148;) providing for the purchase of a hybrid debt-like
instrument (the &#147;<U>Transaction</U>&#148;). Under the agreement, Amarin will receive $100 million at closing, which is subject to customary closing conditions and expected to close no later than December&nbsp;27, 2012. In return, Amarin is
obligated to make quarterly payments to Biopharma that are scheduled to increase yearly until the total amount due under the agreement is paid. The first payment is scheduled in November 2013 and will be no more than $2.5 million. The final payment
could be as early as May 2017. Based on various conditions specified in the agreement and operating assumptions, quarterly payments could be reduced and the repayment period could be longer resulting in an estimated effective compounded interest
rate to Amarin of approximately 12% to 14%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To secure its obligations in connection with the agreement, Amarin granted Biopharma a security
interest in its patents, trademarks, copyrights, know-how and regulatory filings, submissions and approvals related to Amarin&#146;s lead product, Vascepa&reg; (collectively, the &#147;<U>Collateral</U>&#148;). If Amarin (i)&nbsp;fails to deliver a
payment when due and does not remedy that failure within a cure period, (ii)&nbsp;fails to deliver certain reports when due and does not remedy that failure within a cure period, (iii)&nbsp;incurs certain forms of indebtedness above specified
limits, (iv)&nbsp;fails to maintain a first-priority perfected security interest in the Collateral and does not remedy that failure within a cure period or (v)&nbsp;becomes subject to an event of bankruptcy, then Biopharma may attempt to recover its
unpaid scheduled payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the agreement, Amarin may not (i)&nbsp;incur indebtedness greater than a specified amount;
(ii)&nbsp;pay a dividend or other cash distribution on its capital stock, unless it has cash and cash equivalents in excess of a specified amount; (iii)&nbsp;amend or restate its certificate of incorporation or bylaws unless such amendments or
restatements do not affect Biopharma&#146;s interests under the agreement; (iv)&nbsp;encumber the Collateral; or (v)&nbsp;abandon certain patent rights, in each case without the consent of Biopharma. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon an Amarin change of control transaction, as defined in the agreement, Biopharma will be entitled to receive a specified amount less than the then
unpaid scheduled payments if such change of control transaction occurs on or before December&nbsp;31, 2013, and an amount equal to up to the unpaid scheduled payments if such change of control transaction occurs after December&nbsp;31, 2013.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">* * * </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing description
of the terms of the agreement is qualified in its entirety by reference to the provisions of the agreement, which will be filed as an exhibit to Amarin&#146;s Annual Report on Form 10-K for the year ending December&nbsp;31, 2012. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;The information set forth under Item&nbsp;1.01 of this Current Report on Form 8-K regarding the Transaction is hereby incorporated by reference.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(d) Appointment of David Stack </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At a meeting of the Board of Directors of the Company on December&nbsp;10, 2012, in accordance with the Company&#146;s articles of
association, upon recommendation of the Nominating and Corporate Governance Committee, the Company appointed David Stack as a Director of the Company, effective as of December&nbsp;10, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with his appointment and in accordance with Company&#146;s non-employee director compensation policy, Mr.&nbsp;Stack has
been granted an option to purchase 45,000 ordinary shares of the Company. In accordance with Company&#146;s non-employee director compensation policy, the options granted to Mr.&nbsp;Stack have an exercise price equal to the fair market value of the
Company&#146;s ordinary shares on December&nbsp;10, 2012, the date of grant. The options will vest in three equal annual installments commencing on the first anniversary of the date of grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in accordance with Company&#146;s non-employee director compensation policy, for fiscal 2012 Mr.&nbsp;Stack will receive an
annual fee of $40,000 relating to his service on the Board prorated for his service in 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to his current role
as President, Chief Executive Officer and Director of Pacira Pharmaceuticals, Mr.&nbsp;Stack is also a Managing Director at MPM Capital, and Founding Partner of Stack Pharmaceuticals, Inc. Mr.&nbsp;Stack&#146;s experience includes, from 2001 to
2004, President, CEO and a Director of The Medicines Company where he was recognized as the Ernst and Young Entrepreneur of the Year in 2003. Prior to The Medicines Company, Mr.&nbsp;Stack was the President and General Manager of Innovex Inc., Vice
President of Business Development and Marketing for Immunomedics, Inc., and Director of Business Development and Planning for Infectious Disease, Oncology and Virology of Roche Laboratories. Mr.&nbsp;Stack holds a degree in pharmacy from Albany
College and a BS in biology from Siena College where he is currently a Trustee. Mr.&nbsp;Stack is a Director of Medivo, Inc. and PepTx, Inc. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
December&nbsp;6, 2012, Amarin issued a press release entitled &#147;Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring while Continuing to Assess Strategic Alternatives.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the press release, dated December&nbsp;6, 2012, is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
herein. The contents of the press release are deemed to be filed for purposes of the Securities Exchange Act of 1934, as amended. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">* * * <I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>This Current Report on Form 8-K contains forward-looking statements, including statements concerning the planned commercial lunch of Vascepa in early 2013 and actions taken in support of the
anticipated launch, including the hiring of a specialty sales force, Amarin&#146;s continued evaluation of strategic alternatives for the marketing and sale of Vascepa and Amarin&#146;s current expectations regarding the submission of a Supplemental
New Drug Application (sNDA) to the FDA by the end of February 2013 for the ANCHOR indication for Vascepa. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. In particular, there can be no
assurances regarding the amount of Amarin&#146;s revenues from Vascepa or any other source in 2013, and no assumptions should be made regarding such revenues based on Amarin&#146;s payment obligations under the Biopharma agreement described herein.
Nor can there be any assurance as to Vascepa&#146;s acceptance by physicians and patients, the reimbursement decisions of government or private insurances, the timing of future regulatory submissions, the FDA&#146;s response to any of the
company&#146;s current and future submissions, including FDA&#146;s determination of the regulatory exclusivity status for Vascepa and the timing and determination of Amarin&#146;s planned sNDA for the ANCHOR indication, the effects of rapid
technological change and competition, or by Amarin&#146;s other intellectual property rights, or the cost, pace and success of Amarin&#146;s product development and commercialization efforts. A list and description of risks, uncertainties and other
matters related to an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this Current Report on Form 8-K, whether as a result of new information,
future events or circumstances or otherwise. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">* * * </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been filed with the
Securities and Exchange Commission: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit<BR>No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated December&nbsp;6, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: December&nbsp;12, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John Thero</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;Index </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit<BR>No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated December&nbsp;6, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d450150dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g450150ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring while Continuing
to Assess Strategic Alternatives </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- Steps Are Consistent with Amarin&#146;s Continuation of Its Strategy to
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Parallel Process Three Strategic Options- </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>-Conference Call Scheduled for Today, December&nbsp;6th&nbsp;at&nbsp;4:30 p.m. ET- </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">BEDMINSTER, N.J., and DUBLIN, Ireland, December&nbsp;6, 2012 &#151; Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to
improve cardiovascular health, announced today a $100 million non-equity financing with an investment fund managed by Pharmakon Advisors and that Amarin is continuing its preparations to commercialize Vascepa<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (icosapent ethyl) capsules with the hiring of a sales force in the United States. Payments by Amarin under this
hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As
previously announced, the initial commercial launch of Vascepa is planned for early in the first quarter of 2013. The company is hiring 250-300 specialty sales professionals for the launch of Vascepa for its initial indication, the MARINE
indication, which is approved by the U.S. Food and Drug Administration (FDA). Amarin&#146;s goal is for every sales representative hired to have, at a minimum, three to five year existing relationships with the identical physician groups Amarin will
be calling on and educating about Vascepa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to hiring a sales force, Amarin has been focused on continued commercial preparations
for Vascepa which, as previously disclosed, has included, but has not been limited to, finalizing the introduction of Vascepa to managed care plans to gain formulary access, building up inventory levels, hiring key personnel (e.g., managed care,
marketing, sales infrastructure, pricing), developing direct-to-consumer advertising and speaker training and coordinating other pre-launch marketing activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amarin&#146;s hiring of a sales force is part of a continuing strategy to evaluate three potential paths to Vascepa commercialization: an acquisition of&nbsp;Amarin, a strategic collaboration, and
self-commercialization, the latter of which could include third-party support. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This transaction provides Amarin with non-dilutive
capital that will ensure our ability to fully execute on the Vascepa product launch while continuing our strategic partnership discussions,&#148; stated Joseph Zakrzewski, Chairman and CEO of Amarin. This innovative transaction allows maximum
flexibility for Amarin.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa&#146;s next indication, for the patient population studied in the ANCHOR Phase 3 trial, remains on
target for a Supplemental New Drug Application (sNDA) submission to the FDA by the end of February 2013 resulting in an anticipated PDUFA action date for the ANCHOR sNDA before the end of 2013. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference call for investors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amarin will host a conference call and webcast for investors, today at 4:30 p.m. ET to discuss the above topics. The conference call will be webcast live and a link to the webcast may be accessed from the
&#147;Events&nbsp;&amp; Presentations&#148; page on the Amarin corporate website at <U>www.amarincorp.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To listen to the live call on
the telephone, dial 1-877-407-8033 (United States and Canada) or 1-201-689-8033 (International). The conference call ID number is 405508. A replay of the call will be available for 30 days by dialing 1-877-660-6853 (United States and Canada) or
1-201-612-7415 (International), conference ID 405508. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Amarin </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve
cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (icosapent ethyl), Amarin&#146;s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more
information about Vascepa visit <U>www.vascepa.com</U>. For more information about Amarin visit <U>www.amarincorp.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Pharmakon
Advisors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Funds managed by Pharmakon Advisors, including BioPharma-II, invest in debt securities and capped royalties secured by revenues
from life sciences products. Pharmakon Advisors&#146; management team has a long and successful track record of structuring securitized financings and making direct investments in royalty interests on life sciences products. Pharmakon manages
approximately $625 million and has structured investments secured by royalty payments on fifteen different pharma, biotech and medical device products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements,
including statements about the timing of a commercial launch of Vascepa, preparations for commercial launch, the potential for an acquisition of Amarin or a strategic collaboration with a third party for the commercialization of Vascepa, assurances
regarding the amount of Amarin&#146;s revenues from Vascepa and the timing of future payments owed to the Pharmakon-managed investment fund under the financing agreement, and Amarin&#146;s current expectations regarding the submission of a
Supplemental New Drug Application (sNDA) to the FDA by the end of February 2013 for the ANCHOR indication for Vascepa. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors
that could cause actual results to differ materially from those described or projected herein include the following: risks associated with the planned commercial launch of Vascepa and preparations related thereto, including the timing of the hiring
of the specialty sales force, acceptance by physicians and patients of Vascepa, and reimbursement decisions of government or private insurances; the timing of future regulatory submissions, FDA&#146;s response to any of the company&#146;s current
and future submissions, including FDA&#146;s determination of the regulatory exclusivity status for Vascepa and the timing and determination of Amarin&#146;s planned sNDA for the ANCHOR indication; Amarin&#146;s ability generally to maintain
adequate patent protection and successfully enforce patent claims against third parties; commercializing Vascepa without violating the intellectual property rights of others; and uncertainties associated generally with research and development,
clinical trials and related regulatory approvals and commercialization. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S.
Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press
release, whether as a result of new information, future events or circumstances or otherwise. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amarin contact information: </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen D. Schultz </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations and
Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1 (908)&nbsp;719-1315 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>investor.relations@amarincorp.com </U></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g450150ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g450150ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0@$Z`P$1``(1`0,1`?_$`-,```("`@,!`0$`````
M```````*"0L'"`,$!@4"`0$``@,!`0$!``````````````<%!@@$`0,"$```
M!@$#`@,%`P4*"0T````!`@,$!08'`!$($@DA$PHQH=%2%$%1(C(C%1:V87&1
MLG,T%S=WMX&Q0G(SESAX.>%#)%1T)365)M8G&$@1``$"!`,$!08*!@<'!0``
M``$"`P`1!`4A,09!46$2<8&Q(@>1H3(3%#3PP=%"4G*"LB,58M)S)#46X<(S
M8[-T-I*B0U/3)1?B@^-D5?_:``P#`0`"$0,1`#\`?Q5.8I@`H[!T[^P!^T?O
M#1!'%YJGS>XOPT00>:I\WN+\-$$'FJ?-[B_#1!'G[9<JU0JQ/W6\62$J%0JL
M4\G++:+)),H:!@8:/1,X>R<M*OU$&;%DU1()CJ*'*4`#VZ_;3;C[B664J6M9
MDD)$U3Z(_#CB&D%UPI#2<R3*$W;_`.JEKDCW-,-X^Q4G')=O.+M+C&F5LC3<
M(@E9,AO[6L2#99>AEGR19&IX_P`>S(HNFR(>4YDXX7*[HA=VZ*3<9\,G4Z<>
MJ:D_]]4D+;0DDA`3B4JV%2AT\I\]#7K)HWA%.R3["#RJ)EC^EE,2S`F,I$$F
M27/D79'*"3ELX1<MG"2:[=RW.FL@X06(55%=!5,3IJHJIF`Q3%$0,`@(:4$B
M"0H2,^OK[(OP((!!F)?`]<<GFJ?-[B_#1'L'FJ?-[B_#1!!YJGS>XOPT00>:
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MT4;00Z02H]T'`_I$<#@-TYQ7RB`'`2G#J*<!(8H^PQ3!L(#^X(#I_F4LI_#X
M3A3I)21(RD9Q9W^FQ[B1N:'!YAB"_P`Z61SSQ(3A<9V@SQR"DK:L9&:J$Q5=
MU`44,LY,6(8J0SQ78=W47YA]A7+OFCQ$T_\`DU[55TX/L-7WP92`7FH?'URV
M0Z=)W9-QMX:6?WEH`'?R_-._#+R';#%&E_%J@T00:((-$$&B"#1!!H@@T00:
M((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-
M$$&B"#1!!H@C]I_EE_?T01W=$$=5?\L/\T/\8Z((X=$H(-$H(!$I0$QS%(0H
M"8YSB!2$(4!,8YS"(`4I2@(B(^P-'1G!"6>+*95._IWL,_Y1R/#)7O@#P0H4
M_A&BQ+H55*Y>;;8"3E8:2C4Y2%06=35C/,V1-8!$Q&T5%=6X"73AJ'W="Z/I
MZ>F(1?*U0<4?G)`(5(C@`$]*C%!;:1J6^...CFMK*2!LSF!L^<9JF#D`(3]Y
M^\.[KP)Y<YGXN78'#I3'=E6-4+"ND*9+EC>;WE*!;T!$.D?TS75T1<%*(@D\
M362'Q3'3;T[>&;[:6;@RH#G1B,^4C!23QGYH7MYM[EMKG*57HA1Y>(.,^L2/
M#*,]]GKGQ(]NCG3BK.#Y^\1Q3/./Z,\]1;8RATY'%-M=M49.5.U(8`<O*3*(
MM9IN&PG$S(R91`%3;\.K["G4%D<H^7]\0.9M7Z0Q'EQ'7'3IZZ*MMR2[CZA1
MDH<#@?-B.($6XT9*1LW&1TU#/VDK$3#!G*Q,HP73<LI*,D6Z;M@_9N$C&27:
M/&JQ%$SE$2G(8!`1#64BE2%%"Q)0,O)A_1U0]4J0L<Z,4J`(Z-D=W7D?J,49
MUR5,X<P]D3*5?QA>LTS5%K+VP1N*<9-&K_(%[<L^CIK]39/%F[9S,.@.(ID.
M<H#TC]NNJBID5E8U3..):0I6*U>BG#,Q\GW2PRIX(*R!D,X6\S+ZH[&W'6PL
MZIGWMS\Y,+V61:'?QL+DZ`I]+?2;%)0$E7L6G.RS,LHS25,!3JMQ4(4P@`CN
M(:85%X:/7!!505](ZB>:.90GQED>$4^HUHW1D)J*5]!(PGA,;Q,`QAXWK$N'
MY2F,'$ODN82@(@4)?%W4.WV!O9MMQUW?^([ME[4R,"1W5XRV9;8YAKVB]'U+
MH!.?,(:5X[9WH')_!.)N0V+7YY&@9AHT#>JRJMY8/&S.:9D67B9,B)U$D9B#
M?`JR>)E,8$G2"A-QZ=*^X4+]LK7:"I`#K2RD](^7.+O2U**RG15-SY5I!QSZ
MXS-KEC[P:.G*`8F4+6<U?4Y\0^&?)K*7&-]AO,F7IW$4JSK=KN5`?T9"JA:Q
MC6KZ<KK$9V<9R"[NKN77T3PXIE(5XDJF7?HW%C63PVNEYMK5Q#K+(=!4E*@K
MFY09<V&_9PQBGW'6-#;JM5(6E+<29$@@=/GPC72L>KJXQW2PPU2IG"SEE;;7
M8I!O$U^LUD<>SM@G)1V?H;1T/#1<\ZD))\X/X$213.<WV!J1>\)[BPT7GZRG
M0TD3*B%`)&\DR$A'*C75,\L-HIGE+)P$P>R)^^#W,2Z\PZO>;+<N'W)/B$:H
MS4/%14)R1K;&LS%W;2D<L^6F*RS:N5U5(Z)42!!P*I2&*JH4`#VZH5[M+-I?
M2TS5,525))*FS,`[CB<XM5NKG*YM2UM.M2.2P1OW@;N.><;QZA8D(POR%Y#X
M=XJX?N>=\\W>(Q]C*AQBLE.3\LN4AEE`(;Z*%A60#]5-V.9<%!!BP;%4<.ES
M%(0HB.NN@H*NYUK=#1(4Y4K5(`9<2>`&))P`QCX550S24ZJA]7(VG$GX;SA&
MFO:W[HF&.Z=ABY96Q9`S%#F<?Y!F*/<L;6B3CY&SP;7K.^I5G<'CBI)#%7:M
MF(X2_!L@\2=->M06PJ'EM3:9K=-5::2J*7`M(4E:<B1F.KSB1VQP6B\4]X94
M^P)+2<1\G9AA,9F),M5[#9$M*4&B"(@>8O=M5X79$R-6+QP`YY9%QQCF)C)U
M[R!P_BB&N&'9"(>0K.7D9$EA5LT8>.:UT[D[=\=P0A$%4#B(@0.K5KM&E?SB
MF0\Q742*EU7*&7'.5>&&`D<X@:^^?E[Q;735"VD_.0F:.LGY8BQ?^L!X$II`
M:,X\\KI!40$?+<1&+(\GM+T[*AD=YN`E$1WZ?L_=U9T^$M^S<?I0.!6?Z@B#
M7KNVC_@N3^R/C,9%Q;ZEQQG^O3=PXZ=JGG?G.H5J7_0-@LF/(BO6:,AYCZ)M
M(A%OUJPC/D;R7T+M-843"!@14*?V"&OC6>'":!U+%PN=&RX1,!1"2>I2TGS1
MTT^K?:VRY2TCRDI^CS'SA"H\V^]5SQQQY:4:ER,X0\T\`RZFQEHZU5:J%ET4
M@,!57"<'8)NGR3I!(?:9,@[_`.'7Z'A?<*EOUMNK:9Y&PI)D>M(6(_*M9T[*
MPBJ8?;ZAAT\W*?+$M7"_O)]N_GE),ZK@?/T.ADI\`BWQ)DIBZQODIV8!*`I0
M\%8_(:6A8N^XEB73\2@`B.P>.JK>=(W^QI+M;3J+0/IH(6GK(.`Z0(FZ&^VN
MXD!AZ3AR"I3^0Y["8E"\0'[OLV'P\?W?MU6I$F6$I@SWYX2B8(V'TNV(G>=?
M<[NW"2^.*VW[>O,[DA1V%&C[M*9EP12XRR8[BB.%I8DG"R+LSOZYI)U]O&`N
M[ZT@33173-U;;[6BQZ;9O#`<-?3T[BG.4-N*DKI`F)@]N$0MSO#EN<(]F><1
M*<T`D=9EAY8AF'UB/#[[>)O);_S?%W_N7VZN@\([KDFJ8Y?JJQXX3BN?S[1I
M,O4.B7$1E'$GJH\1Y]M2=%P=V]^;.8+D=N9Y^K&-H>EW*:29%.5([YTQ@9AZ
MJS8D4,!176`B0&$`$VXZY*WPPJ;>WZVMKZ9E!VJFD=1)$=%-K1FJ7R4]*^M?
M#'LG&9<G^H8L6%(23L^6^T=W)\=UB%:F?3-GM.-(B.K42R)T^8]DI\[PT0Q:
MI]0=:BJQ2$_RA#7%3:!9JUAMBZV]UTY!*^8GA('..A_5#M.DK>HZD-C,J$AY
MTCMC4D/6(</1\0XF\EA^W_Q?%VW[3;;:F/\`Q%=9>],2^JOY(C_Y^HMK#TND
M1(AVW_4*\.NXSF5]@*!K5]P1E%W&!)X_A,M.ZK]%D\[8%U)F$J<K`2[]M^L\
M2U3*X!@OY:SMN)SH=8I*%"NZCT!=M/4@K5J;J*6??]6#-'T5*W`Q,6G5-!=W
MO9DI+3WS0HY\!QW1/5JC198Q%GO*<AA'#N0,LQ6+LCYJD*+!'FV^*\0Q#6?R
M5=!3=-FYXNH0SU['-I&3(DN9<4A6((I)'Z>HVQ1ZZ&E36UC=(MUME*U2YUF2
M4\2?-'QJ'BPRIX(4LI'H@3)Z(7<S5ZHG!W':Q,:CG#@/STQ!:)!D,FR@LJ4*
MF4&2?QHB4I7\8WGK<@,FS`Y^DRB/40AO`P@/AJ_T?AI67!GU])7T+J9_,652
M(,I3`SVRBIU&LJ>E"14TU0VHC)0"3Y\QQC/O"SOZ0O.[)%%JF"^WOS;E:!:+
MO%4NQYV6J=8<XDQP=\[*WD)FW6B,F7C!./@$S@J[(BJHX3)_S>^V_%>-"&Q,
MN*K;A2>TH;Y@T"><X3Y1.6)R&>,==OU*+DXE%/2O!HD#FV`$RF93&&>)&`Z(
M83U0HL\:9\@NX)PBXM79ECKD;REPOA:]R-=96MC4\A76+KLXZK<@^DHUC-H,
M7IRJGCG;^(=(D4#\)E$#A_DCJ4HK)=[BT7Z&G<=9"I$I3,3$B1Y"/+'%47*A
MI%^JJ7$(<E.1SD9_(8UZ5[UW:714.DIW!.,H*)F$I@+D5@H7J#Y3I$,0X?NE
M$0UW#2>I")^QO=GQQ\Q=[<1,.IEP!^2/D*=\KM%))F4-W`./(E(7<P)V9XL<
M0#Y$THLZB@[_`&%`1'1_)^I2?<W9=(^-4>&\6T&7K,?JJ_5B,7NX^H!X80?!
M#,]?X5\GJ#E[D)E&+'%568T)Q+.).EQ%T;.V-OR"LL]B&;9G^KU7*Y*S/Y@*
M!).&PE`0`PEL^DM#75Z],NW9A2+>R><E7*0LIQ2C!6TY\`=L0=]U#2M6Y2:1
MR=0YW$X*20#F<1GL'5'E^Q]R][2_;^X`8NQ7/\Y>-L9F6\@?+.=Q<V\K61)D
M2WM6J@5ERHZCV[A<M$KK9G#^TZ8+M%CE$?,W'Z:SMFIKW?77TTC_`+(WW&QF
M`D;1B0>94U'@0-D?G3]7:K;;DH4Z@/K[RYS'>.0/=V##IZ8T\]0_4.(7<NX^
MNN:O!G,^,<\Y<X4QD4SY!LL72Z4Y*FX^7F5>)Q<U/)H)IJG_`%"M+5P\0,(&
M$D<XD#"/2D&IGP_J;IINX_DE[:6S3U<RWSC`.`8RQD.8>>41>JV*.[TGMUO4
MA;S/I2G/DV>0YG(`S.4(R[`/M#<H@.^X;@("'V_N#OIYRGW3UPKP2#A@8LE?
M2Z]PX_*#A\_XIY#G32&9.(*$7!PRK]R*TG:<#2QU4:')]:IC+.U:0[05@G)M
MQ\ILFP$P]2NLW^)6GORN[?F=.F5)59@9)<&:>A0[PW]Z64./1UU%=0>RN'\=
MK+ZNX?5.'`%,-!:6V6!SBXP;[>(>`Z((3R]8%!M);!W`]1TFF4%N1MNKSA^F
MFD,FWCYZELRNDFBRB9C%3/\`1E4,01Z#*))B8!Z0V;'A.X6[C6$$R]F!EL,E
M?%%(UNVE=&R#GZP_$?BA)WFUQ5NO"CE/F3C+>R.%97&=H,TB)A9'R26FF3#1
MM/4>VM@*4$CH6&K235P/1N0BQE$_:00!V6:Z,WBVMW!F7(H8CZ)!D1U$2A87
M*A<MU6JE<S2<^&?80>N'(?2.\\B6&B99[?%]G>J8H*SW-&!D'RX"=S2IQZDW
MR=4X\55.HP5VS.FTJB@0!'RI1R<-BI#I/>*]B#-0U?F$]QS\-SZPQ2KK`(.Z
M0WPQ=#7/UC"[:Z>\GO)&&.\#:=A\L.G:3@XPP<=N<:$=SKFK7^WYPCSER9EE
M6IK!5ZTK`XPB')BC^L>6;6!X:A1":)BF^H12EUP>NR@&Y6#-<_L+J;T]:EWV
M\,V]&#:E$N'<A.))W3&`.4R(C;K7"@H%U.'-*2/K'+Y3P$58_.CC#DGC7.8&
ME,U3$O*YFY.X#AN5^2$9HP&D(>7S!=KM(1L>^,8H.!F'5>9-'L@"PB=-\[53
M\`(`:U!8[E2W!MYNB$J&F?+*`/T$I!(X3F`1A("$I=J1VF<0X^27'4!PSSFL
MJE/C(`GB3&Z7IRTDE>\?Q`!5--0".LN*D!5,B@$53PGD(4U2`<I@(J0?R3!X
ME'V#J$\1R1I&IEO;_P`1,=^D?XZSTG[JHM7Q,(@&XB/[XB/^/67QA@<Y_&8=
MHGE'\#1T9REPXGJCWMW16M^JEY#V*_=Q!Q@V+SS9L@8QQ%0:6Y<8A!1JSHF)
M,JS4>[<V)@R:Q?DMK'97E?68/'+]\59\R%Z9F50J:?EET5X7VYJGL?M[C*6Z
MAUQ0#DN^M(R.^6!EL,IB%'K:K<<N/LJ7%%I"1-(R!EE\,YD;(T/[(7<5>=N/
MG'2;U8I5PVP-E@66*>0,?UG,R;TZ8?I_HB]_2A^$\ACF>43?@<`\P6`NT2CL
ML.\[K;3POUD6RA,ZYOO-$F9YA\W[8P\D1>F;M^5W!*UDBG69*'`[3T9]4AG%
ML4S>LY)FTD8YVV?Q\@U;OF#YFLFY9O63M$CAH[:.$3'2<-G+=0IR'*(E,4P"
M`[#K+"IH)2L<JDG$'"6,L=V,.Y)"D@@S!V[^/7'9T1^HQ1GS8V!\UD,`&(;$
M62P,0P`8ABC3)K<#$'<IBF#[!#8==-%[XU^V1VB/C4#]W<^H>PQ2<-OYNA_(
MI?Q"ZV>G(3C.KO\`;J^N>V+$?T>R)"<%N3+@O4"JO+-^FH/4.PE0Q#C$4P`O
ML`0%8V_W^'W:SSXM+*KXPG+EI4_?5\D-707\,=GEZW^J(8GYF\*>/W/'"5KP
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M)$RX'F!EL,]DH;>D;N[<Z)3=0>9YJ6.T@S`GQF#QE*<SC#*9/$0*/B4=P$H^
M)1`?`0$/8(#I='XQ\<6T9F>4HI*<PIII9?RTDD0B2264LBII))$*FFDFG<YL
MB:::9``A$R$``*4````-@UL^A]T;^J.R,ZUWO:^D=@AWOT:;-I_1QSZD?I6W
MZ1+?<#,2O_(2^M*R-6LAN#,RNNCSP:F<%`_E]70)_P`6V_CI*^,!4:FB3^@[
MVMPRM`!(IGC+'N=KD.(9F;H/L/999/D$7K)WC*^MG;-VDFY:.FR]4EDEVSEL
MN4Z*[==(PE.0Y1*8HB`@(#I2T!(KF2G,.H^]%XJI&F="LO5GL,XJ@.+':NS%
MS+X,<B^5W'X'UQO/&;)[&`MN&63))65M6-'E*1LTC9*0H0P.9"TUAP"AU8OI
M,9\Q`?I]W"945M1735-):+U3VNO'*Q4-S2Y\T+YN61&Q)&1V'RPE:.QO7"W.
MUU.2IUI0)3G,8XC><,=NW@8QJ[8)^I6"%M-5F9>LVBLR[&;K]@@WSN(G8"=B
M':;N/E(N1:*(/8V4CGJ!3IJ$,51-0OV"&K0XVS4LEIT!3"TD$'$$$2/2"(@D
M..TSH4@E+J3/HEC/XP1TB+++L+=\.O\`<&H\=QSY$3D5`\T:#!B/GK?31C#D
M%5HAN4%KM66Y01;)W:-;)@>=BD0`1V%ZV)].94C;-^N=%KL-0;A0))M3AQ&9
M:)V$_1.P]`.,IN/3>HF[HV*>H4!7)'^V/EVD;<QM`9.#</$/X?9M_A^_2[BV
M0M7ZK''E+L_:LL%^G*]'2%RQ9F'%<C0K*LV2-,5Q6TSY:O8T&+[H^H3834,^
M%-RW`WE+&22.8!,BF)6+X8U#S>J$,LF33C2YC8>4<PGT$815-8,M.VGF6)J#
MJ9=9D?-YXEJ[7=`J&,NW3P=JM&A&=>@3<7<)6-5@Q(!".)ZYX^@K?:9=R;\I
M=_-V2;=.UU#")CJK&$=5+4-2]67RL??45.&I<$SN2HI2.I(`B7LK2&K53I;$
MD>J2>DD35YXWYU#Q*1%'SJJ7/J;RI7'O%3!';?R=1"T=HWG)[F"G>AR*TM*<
MU,G6BX(U7C7C(:BE%J-U$@.8%0=JK^'3MO9K,Y8D4Q%S>KFW^<R#/+RRD)$S
MQYISGPE$'<F[DM\&C:I%M\HQ=GS3F9]64NN-'75%[T2)B@WX:]C%X42CU'*M
ME=`"COMT=*T)N;P\=_9J9#NC<S57<'[,1A9OQ.%/;B.N/,NJ+WD&X@0O!;L/
M++"8`,C]9D%!0O4&X&$%X0N^X_9[1WUTIJM*D=VNO4ND1^4L7GFDJGMPZ!/Y
M(7<BX7F5W5NZ4F$)AWMPUN4[<S_Z6>JD,K-5[AS;K/6;\J3RY28B4%;=DUU9
M+8Q`2)$Z&JK.&,&Q41/YU_)M6F]-E;CMR7[<,%'O/`*3D)]U/*G/B1%9`KKM
M>`6T4@]FV2Y48&1WDS/FX"&>(2M]XL%6XDP'V-G723RP7C'.;FZA1*`$.J3R
M(9T($(3?<A0]GAOI8N*TJD'\6[IZ>3Y(MR4WPF?);Y;^]$GO'3'67;%A"XU/
MF1B[BO$VF]J66JV6M\9D+.\Q?:L83,,E%D9S2UTBHB=<2L@F^?HND=CMRH&)
MT&ZC'VK5;54S=:AVU.5/(WRJ!>ES!8.SE)&$A$U2L.KIE)K4,A:@00@8%)Z<
M8JLNZ-P:L7;PYK9AXW2:3M:HQDK^MV'K`Z(/_JC$-K5</Z8_!8-TUWL4V!2+
M?"4?PR#!8/#PUJ+2]Z:U!9FJ]&#\N5P;EIP(Z"<4\,82E^MJ[5<%TYQ1L.\'
M$'IWG?,;(X.U_P`X[)V\>:F'N2L2H[7JD-+?JKEZO-3FVM.(+6JWC[M&"AOT
M.'T<U!.38`;P+(L$!]F^O=3V1K4%H>H%#\8IF@[EIF4]4\#P)&V/+%<W+5<$
M5"<4Y$;P=GPVR.R+?6HVVMWZIUB]4V89V&HW2OPUKJT]'*@LPFJ[88YO+0LJ
MR6+^%5J_CG::I!#VE,&LENLN4[JF'@4O(44D',$'$'H,X?#;K;R$N-&;9`(.
M\'&<>AU^(_<*,^KL03-QSX-N1ZO-1Y9G23'?\/0XI$@93<OVB(MR[#]GC]^F
MGX6&5?6_Y7^M%*UK/V5@#:Z?NF,&>K(X&EL>)\(]PFBQ`#-8[8UW"V<SLT`\
MQU1[`H9SC>V/A3)N?]6[8]7BU53#OY4L@`_A2#:4\,+Z&JZHL-0?PW%J6WP5
MDH=!3(](,<&M;6'*5NY-COI`"NB6!/9TRA.GA-RLNG"+E5A+E%0SKJ2V)[K'
MS,K#HK'1)::8[ZXJ\T]V*9B"9M9JH]=M=A'8JBA#^T@:;5]M+5[M3UM>E);?
M=)S"AZ)''F'-T10;37.6ZO;J4'T5#K'PPZ"8N+\3Y/I>;<88]S#CF7;SU#R?
M3:[>JC+ME$U$WL#9HMM+1RAA(<X)KD0<@15,1ZDU2F(8`,40UD:KI7J*J<HZ
M@<K[:RDCB#(P_6'VZEE-0V9MK2".@PKWW`G!^['WFN-_;3@EE);C%P=!+DMR
M_59*'5B)R[-4X]Q$T2440%5LH=!G(QT-Y:@`=,\[(_:@.S'L0_EC2+^H')"X
MUGX3(R(3(CF&V69ZA%3N8-YO3=K3[JQ-3F[&1.SH3O[RMT00>K*220[GE600
M2300;\6,6(MT$B%3111)9\@E3222(`$233*``!2@```>&K[X5%7\MK*L7#4K
MF>I,XJ&N`E-W$LO4HPW2*HU(].1_QC^(?\OE[^Y/(6I/Q'_TC4]+?^(F.'2/
M\<9Z3]U46K6LP?#S"'<8U%YX\N*=P6XD9NY1W4S99IC"FO7]=A'"Y4#6V]R0
MEB:+46_XR*&5L-I>-6YNC<R:)E%!_"01"6LEJ=O5U9MK6'K%#F/T4[5'H$XX
M+E6HM]&[5JS0F0'Z1D`/*1U3A5/A%V3)CFUVHN46?N1B";[F]W"YM[R6QA>+
M$U(27I;N$D9BTXM(1RY+]5$Q669.4>+2:93`0863:%VZFY.EGW?6*+-J>EHJ
M'NV:@"65I3D<.51XE&'VIC;%.I-/FX6AVHJP37U'>03F)3*1F9<^/V2-HA&B
MQUV<J=@GZC:HAW!V:KS4M6;+!2*)D'T1.P;YQ%3,2^0.`'2=,)!JHBH4?88@
MAIVLN-/,!]LA31`4",01F);Q*%@\VNG<4A<PM)ZP9]O9%D-Z8;N1FY7\3''%
M7)D]]=G/B/&Q,%%KR#DZLI=,#N1%C19SK6.=1X[I"R/Z">F`?P(IL3F_$L(Z
MSGXDZ<%JNGYC3)/L-5,\$N'$@](Q'&<.#2%W_,*#V5TCVAK+>1_1ET2AG@?;
MI<Q<#GA&*\Z(J.,(9E;I%ZE5\3Y%13+N`=2BE.F4R%W'P#<Q@\1\-=%)[XT=
MGK$_>$?*I/X#DOH'L,4FK;_0-_Y%+^(76S_F]49R?_M5_6/;%B)Z0ATQC>!?
M(I5_)1K,'O+6:.@1R_;-U3$0Q-BY$YA3643,!14*(%'V&V';V#K/7BNA:M0,
M\H)_=4Y#])4-;0B@BV.<Y`_$&?U1$W_/?NF<0>WKBJS7G+F5:C)WUI#O5J)A
M.M6",F,F9`L@(&_0\0QKL>X=/HF*=O1(#F4>D18M$0.<QQ,!2'IUDTQ=K[5)
M8I6EI9*AS.$$)2F>)).>60F>C.+)<KU06UA3KRTET#!((*B=F`R&.9BI)OMO
MMV=,OW:]OX]W-7_,61+1='D-!LW<F^D;->K$_G7;"(CFB2[YZ8[^3,1%-,AC
MF````WUJMA%/04K;/-RM-(`!)D`$B6)R`A&N>MK'E+;3,J4<<S,X^7Y8L>?3
M.]MK,/!7C#D_)?(."=4G*O*.?I]B1QO)D%.?HF/*7%2J%4;VMN)MXRU3[JR/
M';E@8/-8H"@FKTK^:F3/'B-J.EOER;IZ`A5+3`@J&(4M4N8I.[``?)#;TC:'
M;91%VH$G79892`F1/RG<92F!E#+2?Y1?W]+D_'%N&9Z(I+,R_P!<>7O[5LD?
MMI-ZVA1>Z-_4$9UKO>U]78(>0]&N0H87YWG`I0.;+&%R&,`!U&*2EVX2%,/M
M$"BH80^[<=)+Q>)-=1#^[7VHAEZ!]T>^SVN0X!EW^J;*/]G-X_9B5TI;?[XS
M^T3]^+O5^[._LU]AA2WT<G^S%S,'[N0M-_NX;::GBY_$J3_+J^]%+T'[B[]8
M=BHP5ZA_L)]87;N`<(:4(J[O[3R8P/5F!=E";'=S&9L;0S0@"*Q0`R]BB&Y!
M$X=3YL7<'!#=V@-=RY+%>5[0&G5'*?\`PU'C\U1SR.PQRZHTN5!5QMZ>]B5H
M&6&/,GM(V9B$G*!?KIBZZU+)>-K3,TJ^4><CK13K?7'RL=-U^=BUR.8^4C7J
M!@.FJBJ4-P'<BA!$ARF(8Q1<U13T]<PJG?0EQA:2"%8@I.?PWPN*=Y^E>#K*
MBAU)Z)$19[]C_O54GN:8P)C;*#F#I?,W&<$@K?Z@W,G'Q.4X%F";4<JX[9JG
MZA;K*"3]-1:?4:*=J=1-VJJ0ES3K31[VFZGVBFFNT.'N',H/T5?U3MR..;FT
M[J%F[L!MR2:U(Q'TI?.''>.L81XCU33CR.T#E1/H$PO,MX/;`;?;RQ+=$G76
M(;"(ALVZ=OO-KZ^&4CJMH_W3A_W3'NK"/R@C^]1VSB8/@:F1/@]PN3(4"$)Q
M0X[$(0H`4I"%Q#4`*4H!X```&VVJC>"3=ZHG/VES[YB9M@E;F!_=)^Z(VWU'
M1VQ`+W2L2X4O.>J],9%[/W)+GW,(8LA6*>8<0W=A7:[`1Y+%:#(4,\:XR[1G
M*TW%JN%'RJR;$_YI^D'FFZ>DEZTU5UC%`INGN=+1H+I/(XF9)DGO3Y%8'+/8
M<(K5XIJ5ZJ"GJ)VH5R`<R2H#-7=D#LSRVCJBLD../$4B9D%?32]Q%,1("@JQ
MV3I)=0`*(CL59ER&7`#FZ?$H?B'[O'5E3<;KLU!;O]@?]*(8V^W9FV5/4ISY
M8CG[B1>!O'SCE;9%UV0N97%/)M]82=*POE3/64+I%TB,O[V/472DW+=KEZ;=
M3KVN12*[]!G],HFLJ@4JFR8F$)^P&^7&O0E-XHZFG00I:&T)*I;L4``'?.(F
M[-6RDIB?87VW5X)4I:\#T$XQZ3M[\&\<T;C33&W)7L#\W.6&7+.J]O,AF5"R
MQU-KLC7K$=)Y3V%2B@R94'#6(:UP[=4?JV_UBKI990P]`E(3\7^^/U-R4;;>
MJ&GI$]T(*0K%.<SR',X=$?>UVEA%(#64+SE23.8YP)'*4A*)#8#C%Q2114\O
MTQO-=CTK!T]>68,R@`<H`<4S/>1#-0I/#Q`NY1'[=]5Y=TNH,OY@H\/T/_C,
M2@MMN!Y1;7C/;-6'E(AM+!^,:'AG$./,7XOIBF.Z!3:O'QE6HJSU[)+U.-43
M%]^@G#V2D99ZY<1[AV=,YE'*X]8"`'$H`.E;6U+M95.5%20X\I?>4,E$9$8#
M//(1<V&FFF$(;3RM@2`VCKF9PN]ZH+MYI<I.&B?*2B0Q7.9^'[>3LSX6;8%)
M*TX,DCI*9`@CF2(*S@]1633GFH"(E22;O2E#J7U?O#6_JM=X_+G3^ZU4DXY!
MP>B>$_1/48JFL;4*ZW^U-C\=GSIVGJ./1/?%:X`AX#N`E-[!]NX?8/[VM)$E
M0*9[)'^CKA.$$$@YQ8@>E.[AQ,V\;[+P6R)->?DKC&@>P8M.^<];VQX(L$J?
M:-;^8(JKJ8TM#\60AN()1KYD0H`5,=L]^*5A-#<DWID?NU1(+ED'`!C+9S`3
MZC#=T7=14T1H'#^*SB-Y2<_(3Y"!#:VE7%WA2GU;94E>/?!)!7I,5;F&S(9(
M1V%1(U.DB*@`;@82])]A$/9OII>%OOU;_E?ZPBEZS]WIOVQ^Z89FSM@FA\F>
M/&2./&2X\DA0LO8TDZ%8&XD*=1NTFH<&S:49=?@G)P;WRGC13VI.4"'`=RAI
M>TU8[;KHBOI_[=I[F'&2CAT$8&+2_3HJZ,TSGHK1(G=,8'J.(BG(Y*\?[WQ6
MY`9?XY9+;"WNV&[Y/4::4\LR2$F$2Z,$78&`&$>N+LD.HW?M3@(@9NY(.^M<
MVRXL72W-7&G,V76PKHWCI!PZ0805QI%T%8Y2NB2D*(^'#=PANSL0]ZZH\:>V
MERPQ5G&=0=63A93)K*?'V(DWB9'5XJM[E#Q\1C6+*NX25=K067IM`OEI=1T8
MV9`P`"38W2I=<Z,=K]1TM71B35:X$NR&"5)&*R<AS(\Z>,,+3.H4,6IUEXS<
M9!*)G.9`Y<_I$'K.Z)IO3I\2+CBGBC;N9.=RN)+D]W";F[Y`Y!G99`Y9MO1Y
MEY(26/HA8SDGU38DL27=SATNKI*6323$/S)=J7X@75JKNC=IHA*WT"/4H`RF
MGTB?)*>\<8L.F*(LTAKW<:FH5.9SY<>TDJZQNA77U:'_`!0JY_NN8O\`VIR%
MII>%?^G#_F7.Q$4/77\9'[)']:-1/3D?\8_B'_+Y>_N3R%J2\1_](U/2W_B)
MCBTC_'&>D_=5%JW]VLP$@9YS^3XH=QRA2;NH2<IW8^ZIQH[16/GKI[Q_XY2+
M+D7SDEXE9P,>"K!NV<,Z3(.F@G12>L:W+(1R`&$.F4L_B`'9B(-+3"$Z6TU4
MZIJ4@UM2"U3@[CDJ6Z8YCO"1+.*5=U*O-X;L[9/L[9FX=YE,^1.'2>$-F14/
M'P,5&0<'&M8F%A8]C$P\5'MR-6,9%QC9)E'1[)LB4B39HR:($33(4`*0A0``
MV#2N4M:UJ<4275$DDS,R3,DYXG?%T0A*4AL2"`)#@.$5V_JINW6I@/DW!\WL
M<U\6N*.4;C]&Y)!@U,1C6,_0S`3.GCGH`4FJ63:TR*_((]/G23%\8?Q'#?0/
MA?J$5MO59JCO5-,04$YELG+[)F.B4*C6UI]GJA<&A)IS/@=OR]9B!_MS<V+E
MV^.8.(.3]2^I>L*?,A%9'K#944RW7%5B%*/O=84+^)-1RM$F%RR$X&!&1:MU
M/:35YU)9&[]:GK<LCG4%%!^BL$D'JW;<HK-EN+EKN#=2F<@J1&^>SH(/Q[(M
M_,8Y)I69,=47+.-YUG9J!DBIP-VIT^Q4*HVE:[9(UO*13LHE,;RU#M7)043-
M^-)0#$,`&*(!DFI8<HJA=)4)*7FU%*@=X,H?++S;[*7VC-M201T'X8[HZ68O
MZH<K?V:7S]EI77TI?>F?VB?O"/*C^P7]4]ABDG;?S=#^12_B%UL\$C$8F,ZO
M3#RB,^8]L.9>GA[1/"CN"<+<O9+Y)TB_2]Y@^0%@H$!9:?EC(%"&/K;.AT28
M;)MXJN33.ONWK>3FG)Q7<-5U#=12&$2D`NDQK_5-XL5Z;H[:M`I_4)5)3:%'
MFFH'O$$RF-D,+2EDM]?1+?JDJ+@<E,*.X?-&&W:#$(7>7[9%E[8?+20QNW?V
M*VX4R-&&N^"<C604G,M.UH%2-9JK6.2;(HM75OHLH<&SLQ2)"X;*MG0)D!<"
MEO&C=2-ZCM8>(#=<TJ3J1(`DY*`&23QXB*YJ2TN6JM+0)53+Q23\O#(@#=O$
M;G^GU[J^,N$W(.`Q)R,Q[B,,.90D65>B\^'QO3&.4<+6Z2="WBYF<R(VA4[3
M-XXDEW0-I(CITH>+()'*1@2362/$:^TQ57F@75VUUWVAH8M<R_5K`!F$I)Y>
M;<0`-FV8[]*7NGHJA-/5(;"5&07RIFDF6),IR&,^F>$L;-9)9)PDFX053707
M3(L@X14*JBNBJ4#I+)*D$Q%4E4S`8I@$0,`@(>W6;.4I,U"2I2.^8S!^&^'"
MD@B8)(\W2);#',G^47]_0?CCT9GHBDLS+_7'E[^U;)'[:3>MH47NC?U!&=:[
MWM?5V"'DO1K_`-2O.[^UK#/[%6O22\7??Z+]FOM3#+T#[H]]GM<AO[+O]4V4
M?[.;Q^S$KI2V_P!\9_:)^_%WJ_=G?V:^PPI9Z.7_`&8>9G^\+3?[N&VFGXN_
MQ*C_`,NK[T4O0?N+OUAV*AQ/V@(#L(&#80$`$!`0$!`0'P$!`?$/MTHY&<QG
M%\A"/U#/854QFZNW/CA33>O&[Q=Y9N1.#:O'B(X_>.%#N9?+&/HEF41&ENUE
M#+346@F`1)Q,[0+](*Q&SRT!KL/A%DO*IU'HMN'YPE@@G?\`1)]++/-9ZJTP
M`%7*@3).:TC9Q'#;P^KZ*B&',Q9,P!DZCYIPU<I:A9,QW.-+)3[;!+^2]C)%
MJ;?I.0>I!_&OT#&0=M%BG;.VRATE2F3.("VZVBIJ^D70UJ4N4BDR*2,@?..!
M&,\HH%+4OT-0'Z<E+J58=7P^&(AO7N%=X'&O=([#F2R280]&Y28RRI@!OFG%
M2+HJ:3TBEG,U;Y*H"#E07<A1;"[`0.F'F+1+L3-EQ$HH++J*Q:1JM,ZX;Y)N
M6]QITH7N[I[JSES2ZCTS$,:OOK%ZL`,P*E+B.9.TXXD?)LZ"(<^X0HD;<,>'
MS=(!!)OQ=P`BF`CU"!$L45,A0$P^)A`H!X_;I/W4@W6JW^T.??,7JW_P]C]D
MC[HC:C7!'7$<_+_A-FGDG?X2YXU[AG+#B3&1-2:UQQ0\%J8[_5":D$)>3D5;
M7*(6RIS4F>><MGY&AA3<$1!!LEL3JZA-/6R[TM`P67J&EJ5E1/,YS<TB`)8*
M&`E,8;3$;5T#M2[ZQ+[K29`222!A/'`C$S$Y[A+;/4!SVF^8`D#Z;O@=PIN)
M1$RAW#'#+@O0`"([=-/:@3IVW$1$0V_AU(_S-;__`,FA,S+`*^6<<WY54`^]
MO2EM*MGVL(5#)@+)7=X[N33@N;GWR*Y2<9^,@7.P27(7(9Z<YEH,M:90[&_S
MF-XF#C/U151G,C$C82-?.6Z_U"*(N!`4>D@M,5[&D])?G?L3%/<:@@<B0>6<
MSRA?SA),U$3SF(HSE.;]?10I?<<I6@25$G+#F(F3A.4L=H/"&N&_9]Y%M01*
MW[U7<Y33;%3(@B6YXQ%!)-(H$33*@:BF1\HA`V`HEZ=O#;2P5JJBS5:+;CMY
M5?K1=Q9GTCE]LJ)#](_+&3L5=L;D+CC)5%ODSW=>X-DV'J%IAK!*XZO,UBAY
M3KS'Q;Y%VZJUF0:T!!Z:$FDDA0<^0HDOY1QZ#E-L(<U5J.AJ&%,HM=`V2DCF
M2%S$Q*8/-F,QQCZMVIYM05[54&1!D5$SD098DX&4CAD3MQB7X1W$1]GM\`^S
M_DU5)`#E2))B8RRCYLQ#Q5AAY:OSL<SF(.=C'\--1$BW3=1\K$RC55C)1KYL
ML4R3AF^9KG253,`E.0P@(;#K]I6II0<09+!!!W$;>J/RH)4"E8'(1(SRE%2!
MWC.`Y^W/SNRC@B&!PKBR<*URE@]ZY,=18V+;HZ?GBX1PN<I1</:;+,7D.JH/
MBJ#(JH@'F!K5VCKZG4%C;K#+VA/<7P4!C+IP5]H0BM16LVJXK93/U2N\GB#.
M1[0>()C7W@%S#NG`SESA;E%2S/%SXYM34;A`-%A2"Y8VF#!&9`IRX;@F<)RM
MN%RH"?<$GA$50_$F`AW:@M#%\M+UO>^>GNF4^56:5#B"!TY9&.:SW!RV5Z*E
MLX`XC>-H.6>7"<]D7#&,,E4O,N.*)EK&\VULM`R34H&[4Z>9'`[>4KUDC6\K
M%NB[&,*9SM7)0.0?Q)J`8A@`Q1`,CU%,]253E'4`I?;64D'81@90^Z=YNH83
M4-&;:Q,'I^3*%)O5T65!"I=M^G>8'U4KR+N%F\KP$PH0,;3(GS-O:!05LP!^
MZ(Z:?A8TKUUP>EW132ZYD]@BG:R<2$4[4^^5D]0E.'"6`?\`=[#_`+"R^_\`
MZLEI4N*2IY6/SCVQ<FB"VG?RC#JA%'U<G`\T+:\0]PJB0G3&VQ-C@_/:[)$P
ME2LD:@LZQ1;Y'IW*`RL.D\AEEAV_&S8I^(G#3K\*+X"AZQ/K[Z>^V#N/I)'0
M3S2WJ.Z%SKFUXHN3:<Q)?5D=V(&))^;"XO:7X/RG<%YVX4X^&:.E:!^F0OV:
M7Z(&!*,Q#27#24MB2ZH"!4E;&I]/#MMQ_G4@F(?DZ8>J[VFP61ZN"AZ\@I0D
M_P#,4)"7&7>/`&*AI^W*N=Q;9`_"F"OZH,S_`$<91;S1D;'0L='PT.Q:Q<1$
M,6<7%1K)%-LRCHV/;)M&+%FW2*5)NU:-42)ID*`%*0H`'@&LGDJ6LK425DDG
M>3M\N?3#YP0D!(D$CS16P>K)=>?W28=#HZ19\8,4)B;JW\SSK!?W&^VP`4"]
M>WV[ZT;X52.FBK_[#GG"83VN?XU_[*.U4:H>G(_XR'$/^7R]_<ED+4CXC_Z1
MJ>EO_$3'%I'^.,])^ZJ+)?GSS$H?`SB3F;E%?G+/Z;'55>'J<$Z7*@K=,B2B
M1V%#I;$HG(JLXL%C6134\O<R+4%5C;$2,(9WL=I?OET9MK`,W%XGZ*1Z2NH3
M[,S#@N5:BWT:ZI4II!`&]6P=9\TX5&X!=@3E!R2Q0'.O,?/_`)%\3N0G,-Y+
M9?NU=PP@XC)61JUWEU[555[I-M+779%=_+HO_P!(DCC`9O'H+H)``*$.!6A>
M]>VV@JOR.DHF*J@I9(!7])'=/+W58`B4\)X[(IEMTS45;/Y@_4+;J7B58<TY
M'$9+3*><N,;R+>G,Y&BH86_?`Y[E1W#H*O+VI14`V#<#G3R\F0P[[^PH:B$^
M(=`!C:*4$[N7]2)#^5G\A6.\O2O_`*D8VRKZ7_+F6Z3)TZ_=WSE7E*)4VE(V
MI96C)FW4E>RQR2YX%[*1,ME&40(5H\4_TZ:)G"*9SBGXCL/13^)=)2OA]JV-
M-J`E-"@#(D3R;X81\'](.OH+3E6M0(,@>8CSK/PV0@]F_#&0^.N8,DX+RQ!J
MUO)&)[?,4FWPZFYB(2L.Z,B+EDJ(%!W%2;<4W3-<H=+AJNFH7P,&GI05E/=*
M-%;1J_=G4<R5;9[CEED85E92N4=2JE>F%I,C/A#NGI.NX]^L].M_;ARE8#*3
MU$1ELF<;%9%P8ZC^CN7(O,B8X8J+*&,=6J2[H9AD@4-P9/70%V3;``)3Q3T\
M&WT:@I4S;7W79#)62%'ZV1.^6TPRM$7CUK*K:\J;B<4\=_FQ_P!J'"<Q?U0Y
M6_LTOG[+2NE-2>],@^EZQ(\XB]U']BX!L0>PQ23MOYNA_(I?Q"ZV@-D9U>_M
M5_6/;%C_`.D6063[;V55SEZ4G'+&^"B;<H]0)8_QHDKX;B)>E0-O';?6<_%5
M2%ZC;Y3A[.G''Z:R/DAMZ(PMCD\/QL./=3$H/>4[<D'W*N%UUQ0Q9QR.;:,5
MSD;CU9G@)I'B\C1#(XC6W#TP=3>!R%&$/$O0$P)D%9%R("9L3:N:/U"YIV]-
MU2C^YK5RNC>@G,C>DXCHB:O]J1=K>I@"3J1S)EOVCK[9'9%2[8Z].U*?GZE:
MH=_7[-69B4KEEK\LV.UDH2>A7J\9,0\DU5`IT'L>_;*(JD$/`Y!#6JVW45#2
M762%-*$P1D0<00>B$6XVMATH7@XDRBPW],5W83<E<.!P2SI:!=YWP%7$UL03
M4R\ZY+)^#HHB+1"*%=P<59&TXK**;57\1E5X8[=78PMW)]9\\2M*_E=9^=4:
M?W)]??D/1<.9W`+Q/`S&T0V='7L5U.+>\?WAH=WBG_T]F^1ALQ/\HO[^E;@2
M0,Q(Q=A*9BDKS+_7'E[^U;)'[:3>MGT,C1M$?0'9&=J[WM?2.P0\OZ-E$Y<'
M<Z7([>6MF#$"!-A_%UMZ-8U%-PV]G2Y+M]_CI)>+I_[A1?LU]J896@O='OL=
MKD-\9=$/Z)LH^.P!CF\"(CX``?JO*^T1]FVE+0$"M9']XG[PV]<7:K/[NXGY
MW(O#J)A2WT<O^S#S,$/$/_L)31\/'VXW;#X?PZ:?BZ97*CG@?4'[W"*;H0$4
M+L_I@>8PXGI2X=47OICB700=(+M7**+ELY15;N6SE(BS=PW7(9-9!PBH4R:R
M*R9A*8I@$IBB("&VO9F84)@@B4L,8\(F)2Y@=G;%>CZ@WL-..,DE:N;_``XJ
M2SCCA,/5IC-.)X%J=97`\O(+$^IM]98(@=8^)99ZL)W"10']`.%/``8F+].^
M]`ZZ37@6:[KE<4B2%_\`-EDE1.T#AWL\YPKM5:7-.57"@3^[G$IVI/ZO9ENA
M1AP8Q6SH2F,`&:J)FZ3"`'((=8%/L.QR=9`-L.X;@`^T`TVERE*8()\QP)2>
MN4L(H3!_%2D8`J$_*(NC^&B`->(G$]J!A.#;C9@IN!Q#83^3BZK)]0E`1`!-
MT[ZQQ=9?FM3^W<^^J-!V\?N+)WM(^Z(V;UP1V1\F87=M6#]VQ8GDWK6/=N6<
M:FJ1N>1=H(*JMF)7*H"DW,\6*5,#FW*03;CX!H2E*G$\W=25`%6<AOZH\42$
MJ*1-0$P-YA,#GIR!]2SS'H5DPGBWMX3/%/&MP;3$#;GU(R#1[!DNSUE_UME8
M-3(<G=HAO6HV0CNI%V,8R0<N2*F(#@J9A(9OV"B\.K4^FMK*X5-0F1`6E82D
M[PD).(.\D810KM4ZKKFRPQ3%ILYE)3,]95B.H=8B+KMN\#^_?VQ^0A<_X5X&
M/K.XE*J^H5WH]SN&,#0%QI4C(1LLO%'?1F1FTG"R+64AVSAJ\0$PI*)['353
M,=,UGU'?M#:DH/8*NN*.504DH0L24`0#+DD<%&(*T6W4UHJ_:6J92@4D$$H(
M()!/SANW_)#M/`[E!SGY`R=XC.8/;ZE>&3:N0L,]JMC7S/3LGQUZEWCQRWEH
M9I%U]).4AC1;5--P"RXF35*<2`/44=)B]6RRV_D7::Y-85*,QZM:2D;"2K`S
MX0QK;77*J4H5M*IA*1/TDJGP$B(DBV'[A_@'4!$K!L/W#_`/PUZ((CHYR\E^
M<F!Y>DQ'$'M^R/,EK88.7D;19B9PHV)XNCRK-\W;1L([C[0F>2FE91JH=P"K
M?9-,J?28>H0U.V2WV>N+ANM<*,((D"VM96#G(IP!'&(FYU=QI2$T--[0%#'O
M!,NHY^6$M.YGP*[^'=#Y!,L[Y>X&M*02M5!IC^A46EY'Q&K%5:HM).1FOIW4
MS)Y'-*6&8?2TLNNX=J@D0>HI$DDDR`73ETU?=#:9H314M;ZSF65*4I#G,5&0
MPDB0$@-DYB<X7EZMFI;U5>T.TI2`D``%&`$_TSM)B.T/3Q]XP/\`\86/_65A
M?V_ZQ!U8AXA:2!F*Q.7T'/U(AQI2_;:=4NE'ZT3O=M&-]2GVWZ,TPK'\&&F?
ML`1CEVZKF-<CY5Q;&2M#/(NC/7[6@W>(R,L]B(5T\547-'.VKYHFLJ<Z)41.
M?JHFI#X=:@?]L%<IBM(`4I*%R5+:H<DY\9B+59_YKM37LYIBXP)D`J3/R\^'
M'/HC!'=<XK=_'NJY5QQ>;GV^C8@J&&XB4C<842IY@Q-..8=_/O8V0G[-,6I_
M>V#B6G9!Q"LRI"FV;(-4FI`(03F44/W:7NFAM+TSK-/7EUYXCF4I#F0R`')T
M[\XY;U2:FO+J'5TA0E`,@%).>>/-C.0GE\K$/`7EEWF7<EA'"W-;MFA#18%C
M:ED3E-`9XQHFU8QT;$K)%O-@Q@RE;!(NY-\JS2*[1CW8D4<+&43(F3\V6@7Z
MV:2"7ZZT7($XK2R6W,23Z(40!QR,6NV5]^*FJ6NHRE$I%SF3A+:0">W'/A$I
M?-;BQ3.:W%;-W&&^(IA"Y:HTK`LI-5(%%*W:T2!)4RV-=TU#$=5BU,VCT@E#
MJ,"(E]AAU6+/<WK/=&+FU+G;6#+>-H/2)CKB:N%&W7T;M(L>FC">\9>0YQ"G
MZ<;M19"[>V&,Q9*Y&U!*L\E<SW-[55XP[J.DEZQB''DF[85Q!L^C'CUJ5*^3
MH.)LY`/U&9BQ\P"J$,4MP\0-4LZ@K&:>@456]I',>*U#&>&8&'3.40&E;(NT
MLK=?$GEJEQ"?E)V[@(F<YFYLS]@##Z-ZXW<5K%S!R(M;8>!/BBLWFO8^?M(&
M1:R:TA;E9RRH.&*K*'<-$$E&Y"BLH+H#%\"&U4+524595^HN%2*5F4_6%)6)
M[I`@X[]D3]=455.SZVF:+SDY<LY>>1[.G"$(.Y]P8[UO<TY5S/)JU=MBXXN!
M6G5B@5RDP=XQ[/EB:U5?T@JT/)SSRWQZDO,/7LJX555(V;I%*8B92;$ZC//2
M]]T=IJUBVMW$.#G*R2A8F2!LY3NWPL;Y:]07JM]K72J1W0``I)RGQ&^,5<$>
MV;WL.!G*_$/*ZC=O*WW2P8HE9AT6IV2TX]:1%@B['7)>ISL:L_8WDSN-<K0\
MXL+=R0BGD."D.*:A0$ANN_:ET7?K4[:WZ]*$.`=X)7,$$*!ERXXC*/A:K+J&
MUUJ*Q%*5%)R)3C@1]+CU9\(VU[IN'/4+]U*R5M#)?`JX8RPS0G3F0H6$Z3;J
M$\@F,T[;"R<6NUS4E>4W=PM@LCG11<*(MV[-!0Y&Z"8JJF4B=,5GA_IEM19K
M@[6+])Q25SE.<AW,!/9MVSPB1O-/JF[J2E=,44Z3@E)3+[V)XX89`8S8L[=/
M,?NWNWF"./G,?M86"BP;2/B:+:^35<RE1F%8@X>NUQ5LQMD_C1-].R(.7IHQ
M!%9"/>F2\]?K3(FF'EE7NHK9I8>ON%IN0=<4HJ#);5,E1F0%F0`'1/MBV6FM
MO12W2U](4@``KYALV\H![1/S0P)TC]P_P#JC>6+*1(RC2CFIGSE5@6N4>1XL
M<+)SF;/6.8EV%I@H?+=)Q*2B1S%@@YC9AZ^NA#IS*4N\5,@"38/,2\L3&\!#
M4O9Z&V5SRDW*L%&E">ZHH4OF)V23*4HCKA55M*E*J*G4^X3L4E,NLPB=W(NV
M-WH>XMRVOO*R;[<),1/KI$U2"+3JQEO$4RDFRI\.E"1\E-SCR^,5)JQ/62!"
MN'!6[=,2IID*F`$W%WZ=U)H[3]J1;47$NE$Y*4AP9DDX<IPF3+$PL[S9]07:
MM55FD*"K8"@[`,^;A/KC6_`W97[[/&?,>.L]X9XIVFIY.Q99F5KJ$XGD;"KE
M%"09]::S218JY%!&3AI9DLJT>M5/S;EHLHF;P-N$E<-9:(NE*Y1UE4E3#J>4
MCD<RS^AG/&>^..CT_J6AJ$5-.PH.)5.<T>3TMH^$C*&T+QSC[ZEQP/9:(EV7
M6\1ERTT::J;R\)\H<3NJ%'RTW$.(E>QQ]+6F!FU6[<7)ETF"TF8.H`(9P8NY
MA5;-CT4U6I>_.0:-*PKE]2YSX&<N;EEU\O5%Z=N&HG*=30M\G%`CF]8B6Z<N
M:?5S0F@GZ>#O%ID3('#"QCY9"E`1R5A?QZ0`-Q_^1?MVTX?_`"#I&4O;`/L.
M?J0O5Z5OZUE7LZA,D^DC;]J&'^T%`][GM7X;O6!93M3/\ZX\LM\D<EPCAAR#
MPU0;7`6.7AXB'F&+AVO9;'&S4,]2@6RB("FW6;J^9^)0IR@1>ZO<T=JBM1<&
M[H&:A+?(9M.*!2"2G`)$B)XG'HBW6).H;,P:9=$7&5*GZ:`1D-A5/`;H<XJ$
ME-SE4JTW8ZXO4+%,5R$E9ZIN'S:4<5::D(QJ\E:XO)LO^A2*T&^64;&71_-+
M&2$Y/PB&E`\E"'EI:/.TE9`5*04!\X`XB>Z+^A2RR%+!2LB9&[A.$GO4.=B3
M.N:>2,)RWX(X:?Y*D\T$7:<@L>U=]7(AU%7^&:($CLGM$9Z4A&BS2[1*8-Y,
M$CF4+),P7,`BZ.8')X?ZZHJ*WJM5[=]6AD_AK(49IV)P!/=F9<)#9"\U5IEZ
MJJ4UEL05*6.\!+/?B1*?;/?$'F".T!WSN-68<=YYPUP^RK4,G8MLS"UU&>;6
M'&*I$'[$QBK,I!H:]E2DH679**M'S13\TZ:+*)'_``F'5VK]7Z)N5&Y0U=6V
MJG=24J'*N<CN/+@=L]A$5RCT_J2AJ$U+#"PXDS&*?UOAD<)B&_XCN4]]!6@$
M8/>QZ_/E5.+%%>QI\BJ)%T%:7^G%(LHA67CQS.)M!=_G19?I-0P$_`#C_+TH
M5Z>T9[1-%Y'LLY\I:<YI;!S2E_N]47[\VU%ZD`T!+\I3"TCKD>SF,)I6#L*=
MY2S6">LTIPEN0REDFY>PR8M[EB1%N,C.2+F4?BW1_I!-Y*`NW1^@FX])=@W'
M;3C;UYH]E`;36#E2`!-*SD-_*(7;NF=0/N%U5,J9XH_6B93M`8=[YO:7>9>B
MH3MAR^;,>9H=U26LE;E<OXUITS#3U/;2[&/EJ]-M;;.,P*]83!TG2"[,_F>4
MD)3DZ1`U-U=7:*U6&G%7'U-2R%!)#:R"%2](<H)RWB+'86=26-*T)HRXVN6!
M4@'">WF._<8D=YE<N_4%\B\'Y(PIASM+.^/HY-K<G39;([C/&-[]<(:LSS96
M/L"5:9A.5F(CIF2BEU&Z;Q4'`M`5,=,GF`0Y*[9[7H.WUC576W3U_JU<W(&E
MI22,IB1PG$K7UVIJJG73,4'JPM,B>9),CA*?,-G3$;G:&PYWZ.U#(9(KM8[;
M+W,F),N/868L]#L.4\6T^2B[7`M3QK"RUNWM+C*@Q.O$*"V=MG+5=!<J:1BB
MF<@B>R:LK="ZJ2TM=P+%4R"$*#:RF1,Y*$ID;L1$78FM3V3G`I2XTO&14@8S
MSGS<3O\`-#M7&7(^8<M86J5]SQ@62XSY2FCS9+)AF5ND!D-[5`CYN0CHM52V
MU<I823+-Q39%\4$@W1*X!,_XRFTFKA3TM+5J9HGA4TX&#@24@SX*Q$H85(Z^
M\P':ELM.GYLYRZ\(SUL/W#_`.N'`YQTQTY*,CYJ.D(>8CF4M$2S%W&2L5)M$
M7\=)QC]NHU?1T@R<D5;/6+ULJ9-5)0IB*$,)3`(#KU*UI6E:3)8(Q&!!&1GL
MCQ24J1R*Q1(S!QG/"*YKOR]@*Y<4KG(\D>$F.;9>^,V0Y54E@Q12H27MUIP-
M<)51=4L?$PD0T?34IBB:7-TQZQ2+*0ZP_2+CY0MU#:`T3KU%RI_RZ\K2BO;$
MPLD`.`;2<@K?OSEG)6Z@TLY2UB:NWIG3+6"0/FGXAN\F<IO]\4HQ_#<8.-41
M)M'+&2B<!8;C9%D[;KM73-\QQU7&KMJY;.4TG#=PV<)&(=-0I3D,`@8`$!#2
M+N:@NYU"DR*2^Y(C&?>)AE422BB92<PTD>1(C877%'3!H@@T00:((-$$&B"#
M1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!
HH@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
